{"id":34629,"topic":"peptides","source":"搜狐网","title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","url_hash":"87968be03b9697de3bf010ee67ab888632666c61","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMijAFBVV95cUxNdUhDalhqdTFoVDNEV0QzdWdJb2pfX2NkU002Wm5yM0c1T2NPendFOVkyRUItRDRpaDd1ZTlwWERZTWFvdF9KZjVpNjgzdU5ENGV4eDJOTXBOb3pfakk0Zkp4aUczbjdlN3VTNU9vYUZOUzItdXN1cUpucGQtNlpaaEI4X1NuTF82UXV3aA?oc=5\" target=\"_blank\">圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","content":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","image_url":"//q5.itc.cn/q_70/images03/20260712/0994a669f53f4f6c8598a342d80b2d80.png","lang":"zh","published_at":"2026-07-12T09:42:42+00:00","fetched_at":"2026-07-12T10:15:11+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","cluster_id":1712365,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}},"news_item":{"id":34629,"canonical_url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source_url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","source_name":"搜狐网","author":null,"published_at":"2026-07-12T09:42:42+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMijAFBVV95cUxNdUhDalhqdTFoVDNEV0QzdWdJb2pfX2NkU002Wm5yM0c1T2NPendFOVkyRUItRDRpaDd1ZTlwWERZTWFvdF9KZjVpNjgzdU5ENGV4eDJOTXBOb3pfakk0Zkp4aUczbjdlN3VTNU9vYUZOUzItdXN1cUpucGQtNlpaaEI4X1NuTF82UXV3aA?oc=5\" target=\"_blank\">圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","full_text":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","excerpt":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 127 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","source":"搜狐网","date":"2026-07-12T09:42:42+00:00","content":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 127 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/34629","export_markdown":"/api/items/34629/export?format=markdown","export_json":"/api/items/34629/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"formats":{"full":{"id":34629,"title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","author":null,"published_at":"2026-07-12T09:42:42+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","full_text":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 127 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}},"actions":{"read":"/item/34629","export_markdown":"/api/items/34629/export?format=markdown","export_json":"/api/items/34629/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"}},"digest":{"id":34629,"title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","topic":"peptides","published_at":"2026-07-12T09:42:42+00:00","excerpt":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","quality_bucket":"medium","quality_reason":"Medium confidence: short full text extraction produced 127 characters.","reading_time_min":1,"cluster_id":1712365},"card":{"display_title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","subtitle":"搜狐网 · 2026-07-12","summary":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","badges":["quality:medium"],"links":{"read":"/item/34629","original":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"quality_warning":null},"export":{"title":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79% - 搜狐网","url":"https://m.sohu.com/a/1049305805_120988533?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","source":"搜狐网","date":"2026-07-12T09:42:42+00:00","content":"圣诺生物：预计2026年上半年净利同比增长43.23%-64.79%\n以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示：\n资料显示，公司主营多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1049305805_120988533%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 127 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 127 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":127,"summary_length":127,"usable_text_length":127,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":127,"summary_length":127}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}